Interviews

Nick Dyer

2024-05-03

Catalyst offers two primary solutions: Catalyst Flex and Catalyst Oncology. Catalyst Flex, built upon the foundations of Triangle Biostatistics and Catalyst Clinical Research, provides standalone services in data sciences and clinical operations across multiple therapeutic areas.

Philip Kantoff

Co-Founder & CEO

Convergent Therapeutics

2024-05-03

Convergent is focusing on delivering targeted treatments more efficiently. We are pioneering the use of alpha particle radiation, specifically actinium-225, to target cancer cells.

Arnd Kaldowski

CEO

Sonova Group

2024-05-02

Sonova’s hearing aids amplify sound signals to stimulate the remaining hair cells, while cochlear implants bypass these cells entirely, converting sound directly into electrical signals.

Sam Deutsch

Chief Scientific Officer

Nutcracker Therapeutics

2024-05-02

Our platform at Nutcracker Therapeutics consists of several components: the biochip, the hardware interface, purification processes, and the software that orchestrates everything.

Sucheta Govil

Chief Commercial Officer

Covestro

2024-05-02

We are focused on forging strong partnerships and prioritizing materials that contribute to a circular economy, which allows us to maintain competitive advantage and support our customers in achieving their sustainability goals.

Doug Langa

Executive Vice President

North America Operations at Novo Nordisk

2024-05-02

Decades ago, Novo Nordisk took a stand that obesity is a disease, and the shame in our society needs to stop. We are committed to driving meaningful change - and it’s not just about effective medicines but other real barriers like stigma and bias. Because obesity is not a personal failing; it’s a matter of health – and people deserve respect, support and care.

Cara Brant

CEO

Clinical Trial Media

2024-05-01

The future of clinical trials is heavily tied to advancements in technology, particularly artificial intelligence (AI) and machine learning, which we are integrating to enhance data automation and improve patient tracking throughout trials.

Tracy Garrison

CEO

GEON Performance Solutions

2024-04-30

By innovating across the supply chain and maintaining close relationships with raw material manufacturers and customers, GEON aims to deliver tailored solutions that address the evolving needs of its main markets, including building and infrastructure, transportation, and consumer electronics, among others.

David Spencer

President & CEO

Prytime Medical Devices

2024-04-30

Our latest innovation, which we call Prolonged REBOA, incorporates a design that allows for controlled, continuous blood flow past the occlusion site to maintain perfusion of the kidneys, liver, and other organs.

Emily Leproust

CEO

Twist Bioscience

2024-04-27

Traditional DNA synthesis took about 10 days, but with Express Genes, we have halved this time to just 5 days.

Pagina 56 din 154